San Diego-based Illumina will begin filling orders for its high-throughput gene sequencing tests and two other diagnostics by the end of the year, following FDA 510(k) clearance of all four devices.
The agency called the clearances a major advance for personalized medicine. Used together, the Illumina MiSeqDx instrument platform and Illumina Universal Kit reagents will allow laboratories to sequence and validate any part of a patient’s DNA to look for abnormalities. They were cleared through the de novo process for novel devices that do not pose a high risk to patients, based on safety and efficacy performance “across numerous genomic segments spanning 19 human chromosomes,” the agency said.
CDRH Director Jeffrey Shuren called the clearance a win for personalized medicine and regulatory science. “Knowing the potential of next-generation sequencing to advance personalized medicine, FDA researched next-generation sequencers to understand how they work and their likely limitations,” he said. “By the time Illumina … walked in the door, FDA had the expertise and tools needed to timely review the submissions for the next-generation sequencers.”
The company’s two cystic fibrosis detection tools also garnered 510(k) clearance. The Illumina MiSeqDx Cystic Fibrosis 139-Variant Assay checks a patient’s gene sequence to determine what variant of cystic fibrosis he or she may have, while the Illumina MiSeqDx Cystic Fibrosis Clinical Sequencing Assay examines a large chunk of the patient’s cystic fibrosis gene to understand how it differs from a reference gene. To obtain clearance, Illumina submitted data on both diagnostics compared with human reference genomes.
Getting your device cleared is not always as easy as it seems. Regulatory Challenges of Device Acceptance will teach you tips and tricks to making sure that your devices get cleared every time. Make sure you get a copy now.